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Abstract 
O-Perbenzoylated 4-phenyl-[C-(β-D-glucopyranosyl)formaldehyde]semicarbazone was 
prepared in the reaction of O-perbenzoylated β-D-glucopyranosyl cyanide and 4-
phenylsemicarbazide in the presence of Raney-Ni. Acylation of O-perbenzoylated C-(β-D-
glucopyranosyl)formaldehyde semicarbazone furnished the corresponding 4-acyl-[C-(β-D-
glucopyranosyl)formaldehyde]semicarbazones. The reaction of O-perbenzoylated C-(β-D-
glucopyranosyl)formaldehyde semicarbazone with the corresponding thiosemicarbazide 
resulted in O-perbenzoylated C-(β-D-glucopyranosyl)formaldehyde thiosemicarbazone and its 
4-phenyl derivative. Acylation of O-perbenzoylated C-(β-D-glucopyranosyl)formaldehyde 
thiosemicarbazone provided the corresponding 4-acyl-2-acylamino-5-(β-D-glucopyranosyl)-
Δ2-1,3,4-thiadiazolidines. Oxidative transformations of these precursors gave O-protected 2-
(β-D-glucopyranosyl)-5-substituted-amino-1,3,4-oxa- and -thiadiazoles. The O-benzoyl 
protecting groups were removed under base-catalyzed transesterification conditions. The C-
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glucopyranosyl heterocyclic compounds proved inactive against rabbit muscle glycogen 
phosphorylase b, however, the semicarbazones showed moderate inhibition (best inhibitor 
was 4-phenyl-[C-(β-D-glucopyranosyl)formaldehyde]semicarbazone (Ki = 29 μM).  
 
Keywords 
C-glycosyl-formaldehyde (thio)semicarbazone, C-glycosyl-1,3,4-oxadiazole, C-glycosyl-






































































Glycogen phosphorylase (EC 2.4.1.1) inhibitors (GPIs) have been considered as possible 
means for therapeutic intervention in type 2 diabetes and some other diseased states (e. g. 
early cardiac and cardiovascular disease in non-diabetics, cardiac arrhythmias, ischemic 
injuries, tumour growth) as rationalized in the recent review literature.
1-5
 Among several 
compound classes
4,6
 glucose derivatives are one of the most intensively investigated 
inhibitors.
5,7
 The quoted review articles
5,7
 provide the reader with a detailed description of the 
structure–activity relationships (SAR) of glucose analogue GPIs, therefore, only those 
features are summarized hereinafter which form the direct basis of our compound design. N-
Acyl--D-glucopyranosylamines8 (Chart 1, I: e. g. for R = 2-naphthyl Ki measured against 
rabbit muscle GPb (RMGPb)
9
 was 10-13 M8,10), N-aryl-N’--D-glucopyranosyl ureas4,11 II 
(R = 2-naphthyl: Ki (RMGPb) 5.2 M), as well as N-acyl-N’--D-glucopyranosyl urea 
derivatives
4,12
 III (R = 2-naphthyl: Ki (RMGPb) 0.35 M) have been shown to inhibit the 
enzyme in the low micromolar range. As a part of a program to replace the NHCO moiety of 
the above compounds by non-classical bioisosteric heterocyclic linkers, among others we 
have carried out the synthesis of compounds IA.
13
 Enzymatic tests as well as crystallographic 
studies revealed high similarity of the amide (see Ki of I above) and the 1,2,3-triazole type 
(for IA R = 2-naphthyl: Ki (RMGPb) 16 M) inhibitors both in binding strength and 
structural features of the enzyme-inhibitor complexes.
10
 Applying the isomeric oxadiazoles B, 
D, and E as linkers resulted in inhibitors of varying efficiency, whereby the 3-aryl-5--D-
glucopyranosyl-1,2,4-oxadiazole (IE type) derivatives proved to be the most potent 










































































Herein we report on the synthesis and enzymatic test of compounds of type II and III with 
1,3,4-oxadiazole B and 1,3,4-thiadiazole C as linkers representing bioisosteric replacements 
of NHCO moieties of N-substituted-N’--D-glucopyranosyl ureas. These studies contribute to 
an extension of SAR related to interactions of inhibitors in the β-channel of the enzyme which 
can accommodate aglycons of glucose analogue compounds and is lined with amino acid side 




2. Results and Discussion 
For the formation of the heterocyclic parts of the target compounds oxidative ring closure of 
(thio)semicarbazones (similar to that applied for the syntheses of IB
15
) was envisaged as the 
key step. To this end, the protected C-(-D-glucopyranosyl)formaldehyde semicarbazone 2 
was prepared by a reaction of NH2C(=O)NHNH2 with O-perbenzoylated -D-glucopyranosyl 
cyanide
17
 1 in the presence of Raney Ni and NaH2PO2 at 40 C (Scheme 1) as described 
earlier.
18





































































was obtained in a similar way using PhNHC(=O)NHNH2 as the trapping agent. 
Debenzoylation was performed by the Zemplén protocol to result in moderate yields of 
semicarbazones 6 and 7.  
 
In order to get thiosemicarbazones 4 and 5, acid catalyzed transimination of 2 was carried out 
because the direct transformation of -D-glucopyranosyl cyanide 1 into thiosemicarbazones 
failed. Thus, semicarbazone 2 was reacted with NH2C(=S)NHNH2 or PhNHC(=S)NHNH2 in 
glacial AcOH at 70 C to give the corresponding thiosemicarbazones 4 and 5, respectively. 
Removal of the benzoyl protecting groups in 4 and 5 was carried out by LiOH in MeOH to 

































2 R = H,   X = O (90 %)
3 R = Ph, X = O (64 %)
4 R = H,   X = S (85 %)
5 R = Ph, X = S (87 %)
6 R = H,   X = O (63 %)
7 R = Ph, X = O (48 %)
8 R = H,   X = S (95 %)










Scheme 1. Reagents and conditions: (a) RNHC(=O)NHNH2, Raney Ni, NaH2PO2, H2O, 
AcOH, pyridine, 40 C; (b) RNHC(=S)NHNH2, AcOH, 70 C; (c) NaOMe, dry MeOH, 25 
C; (d) LiOH, dry MeOH, 0 C.  
 
To obtain precursors for compounds IIIB semicarbazone 2 was treated by acid chlorides in 
CH2Cl2 in the presence of Et3N to give O-perbenzoylated 4-acyl-[C-(-D-
glucopyranosyl)formaldehyde]semicarbazones 12-15 in satisfactory yields (Scheme 2). Under 
these conditions no reaction took place with thiosemicarbazone 3. Acylation of 3 in dry 





































































1,3,4-thiadiazolines 16-19 as inseparable mixtures of two diastereoisomers in good yields. 




Ring closing reactions of the precursors under oxidative conditions were studied next. 
Semicarbazone 3 was reacted with Pb(OAc)4 in glacial AcOH at 70 C to furnish O-
perbenzoylated 2-phenylamino-5-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-1,3,4-
oxadiazole 10 (Scheme 2). Trials to use other oxidizing agents such as FeCl3 or PIDA failed, 
3 was recovered in these reactions. Deprotection of 10 was achieved by the Zemplén method 
to give 11 in an excellent yield. Thiosemicarbazone 4 resisted to several oxidation reagents 
(PIDA, Pb(OAc)4, FeCl3, Br2, K3Fe(CN)6). Semicarbazones 12-15 were reacted with PIDA in 
CH2Cl2 at rt to get O-perbenzoylated 2-acylamino-5-(β-D-glucopyranosyl)-1,3,4-oxadiazoles 
20-23 in good yields (Scheme2). Thiadiazolines 16-19 were oxidized in a similar way to 
result in 1,3,4-thiadiazoles 24-27. Debenzoylations were performed by the Zemplén protocol 







































































Scheme 2. Reagents and conditions: (a) Pb(OAc)4, AcOH, 70 C; (b) NaOMe, dry MeOH, 25 
C; (c) RCOCl, Et3N, dry CH2Cl2; (d) RCOCl, dry pyridine, 80 C; (e) PIDA, CH2Cl2, 25 C.  
 
The deprotected compounds were tested for their inhibition potency against rabbit muscle 
glycogen phosphorylase b (RMGPb) according to the protocol described earlier.
20
 The results 
are summarized in Table 1 also showing the inhibitory efficiency of some relevant reference 
compounds.  
 
Replacement of the NHCO moiety in compound type II (entry 1) by a 1,3,4-oxadiazole ring 
(11) resulted in a loss of inhibition. A similar observation was made with compounds type III 
whereby on changing the NHCO group of the acylurea derivatives (entry 2) to either 1,3,4-
oxadiazole (entry 3, 28-31) or 1,3,4-thiadiazole (entry 4, 32-35) the efficiency was lost. These 
findings resemble those obtained with compounds type IB in Chart 1 where 1,3,4-oxadiazole 







































































follows from these results that the 1,3,4-oxadiazole and 1,3,4-thiadiazole moieties cannot 
contribute to favourable interactions in the β-channel of RMGPb. 
 
Interestingly, semicarbazones 6 and 7 (entry 6) and thiosemicarbazones 8 and 9 (entry 7), the 
“open chain” precursors of the target compounds of this work, showed week to moderate 
inhibition. Semicarbazones 6 and 7 are better inhibitors than the thiosemicarbazone 
counterparts 8 and 9. Phenyl derivatives 7 and 9 are more efficient than the unsubstituted 
compounds 6 and 8, respectively, and this is in agreement with the general trend to show 
stronger inhibition by those compounds which have a large(r) aromatic part in the aglycon.
4
 A 
comparison of 7 (actually the best inhibitor in this study) to the biuret type inhibitor (entry 5) 
indicates no significant difference in the inhibition constants. This may reveal that 
interactions of the whole NHCO linker moiety or its carbonyl group has probably less 







































































Table 1. Inhibition of rabbit muscle glycogen phosphorylase b (RMGPb) by selected glucose 
derivatives and the new compounds (Ki [) 
 
  
Entry linker R linker R 
1 NHCO 
   
 18
4





















 29 No inh.
a
 30 No inh.
a







 33 No inh.
a
 34 No inh.
a
















 linker X H 
 
5 NHCO O  -       21
4
 
6 CH=N O  6 332
b
  7   29 




No inhibition at a tested concentration of 625 M. 
b









































































The reductive transformation of D-glycopyranosyl cyanides in the presence of acylhydrazines 
was extended to the preparation of new anhydro-aldose semicarbazone and thiosemicarbazone 
derivatives. Acylation of semicarbazones yielded the expected 4-acyl semicarbazones, while 
under similar conditions thiosemicarbazones gave O-peracylated 4-acyl-2-acylamino-5-(β-D-
glucopyranosyl)-Δ2-1,3,4-thiadiazolines. Oxidation of the aforementioned precursors resulted 
in protected 2-(β-D-glucopyranosyl)-5-(substituted-amino)-1,3,4-oxa- and thiadiazoles, 
respectively. After O-deprotection enzyme kinetic measurements showed the 1,3,4-oxa- and -
thiadiazoles to be inactive against rabbit muscle glycogen phosphorylase b. However, the 
precursor “open chain” 4-phenyl semicarbazone proved to be a low micromolar GPI, 
equipotent with a biuret derivative of similar chain length between the sugar and the aromatic 
part of the molecule. Replacement of the oxygen by a sulphur atom caused the loss of activity. 
This latter finding may indicate a difference in contribution to the binding of the two NHCO 




4.1. General methods 
Melting points were measured in open capillary tubes or on a Kofler hot-stage and are 
uncorrected. Optical rotations were determined with a Perkin–Elmer 241 polarimeter at room 









C) spectrometers. Chemical shifts are referenced to TMS 
as the internal reference (
1
H), or to the residual solvent signals (
13
C). Microanalyses were 
performed on an Elementar vario Micro cube. ESI-MS were recorded with a Thermo 





































































(Merck). TLC plates were visualized under UV light, and by gentle heating with a 
commercially available heat gun without any charring reagent. For column chromatography 
Kieselgel 60 (Merck, particle size (0.063-0.200mm) was applied. Organic solutions were 





Raney Ni (3.53 g, from an aqueous suspension, Merck) was added at rt to a vigorously stirred 
solution of pyridine (14 mL), H2O (9 mL), and AcOH (9 mL). Then, NaH2PO2 (1.76 g, 20.0 
mmol), (2,3,4,6-tetra-O-benzoyl--D-glucopyranosyl) cyanide17 (1, 1.50 g, 2.48 mmol), and 
PhNHC(=O)NHNH2 (0.75 g, 4.96 mmol) were added to the mixture. The reaction mixture 
was stirred heated at 40 °C. When the reaction was complete (TLC, 1:2 EtOAc–hexane) the 
insoluble materials were filtered off with suction, and washed with EtOAc (3 x 15 mL). The 
organic layer of the filtrate was separated, washed with 10% HCl (2 x 15 mL), saturated 
NaHCO3 solution (3 x 20 mL), H2O (2 x 15 mL), dried, and concentrated under reduced 
pressure. Traces of pyridine were removed by repeated co-evaporations with toluene. The 
crude product was purified by column chromatography (2:3 EtOAc–hexane) to yield 1.17 g 
(64%) of 3 as a white amorphous product. [α]D = +33 (c 0.52, CHCl3); Rf : 0.44 (1:1 EtOAc–
hexane); 
1
H NMR (CDCl3, 360 MHz)  (ppm) 10.36 (1H, s, NH), 8.20 (1H, s, NH), 8.05-7.02 
(26H, m, Ar, CH=N), 6.08, 6.03, 5.77 (3H, 3 pt, J = 9.2, 9.5 Hz in each, H-2, H-3, H-4), 4.67 
(1H, dd, J6a,6b = 12.7 Hz, H-6a), 4.53 (1H, dd, J1, CH=N = 4.1 Hz, J1,2 = 9.1 Hz, H-1), 4.40 (1H, 
dd, H-6b), 4.25 (1H, ddd, J5,6a = 3.0 Hz, J5,6b = 4.5 Hz, J4,5 = 9.9 Hz, H-5). 
13
C NMR (CDCl3, 





































































(Ar), 76.3, 76.2, 74.3, 69.3 (C-1–C-5), 63.0 (C-6). Anal. Calcd. for C42H35N3O10 (741.74): C, 
68.01, H, 4.76; N, 5.67. Found: C, 69.00; H, 4.83; N, 5.62. 
 
4.3. C-(2,3,4,6-Tetra-O-benzoyl--D-glucopyranosyl)formaldehyde thiosemicarbazone 
(4) 
C-(2,3,4,6-Tetra-O-benzoyl--D-glucopyranosyl)formaldehyde semicarbazone18 (2, 1.50 g, 
2.25 mmol) was dissolved in glacial AcOH (65 mL) and then NH2C(=S)NHNH2 (0.83 g, 9.05 
mmol) was added. The mixture was stirred and heated at 70 °C. The reaction was monitored 
by TLC (1:1 EtOAc-hexane). When the reaction was complete, the reaction mixture was 
diluted with H2O (200 mL), and extracted with EtOAc (4 x 20 mL), and washed with 
NaHCO3 (3 x 25 mL), and H2O (1 x 20 mL). The organic phase was dried (MgSO4), and 
evaporated under reduced pressure. The crude product was purified by column 
chromatography (1:1 EtOAc–hexane) to give 1.30 g (85%) of 4 as a yellow amorphous 
product 4. [α]D = +11 (c 0.35, CHCl3); Rf  : 0.33 (1:2 EtOAc–hexane); 
1
H NMR (CDCl3, 360 
MHz)  (ppm) 9.94 (1H, s, NH), 8.07-7.10 (21H, m, Ar, CH=N), 6.34 (1H, s, J = 2.4 Hz, 
NH), 5.98, 5.87, 5.71 (3H, 3 pt, J = 9.5, 9.8 Hz in each, H-2, H-3, H-4), 4.66 (1H, dd, J6a,6b = 
12.5 Hz, H-6a), 4.49-4.43 (2H, m, H-1, H-6b), 4.22 (1H, ddd, J5,6a = 2.9 Hz, J5,6b = 5.0 Hz, 
J4,5 = 9.9 Hz, H-5). 
13
C NMR (CDCl3, 360 MHz)  (ppm) 179.2 (CS), 166.1, 165.9, 165.8, 
165.1 (CO), 139.2 (CH=N), 133.7-128.3 (Ar), 76.9, 76.4, 73.9, 69.6, 69.1 (C-1–C-5), 62.9 (C-
6). Anal. Calcd. for C36H31N3O9S (681.71): C, 63.43, H, 4.58; N, 6.16; S, 4.70. Found: C, 









































































C-(2,3,4,6-Tetra-O-benzoyl--D-glucopyranosyl)formaldehyde semicarbazone18 (2, 1.00 g, 
1.50 mmol) was dissolved in glacial AcOH (43 mL) and then PhNHC(=S)NHNH2 (0.83 g, 
9.05 mmol) was added. The mixture was stirred and heated at 70 °C. The reaction was 
monitored by TLC (1:1 EtOAc–hexane). When the reaction was complete, the reaction 
mixture was diluted with H2O (150 mL), and extracted with EtOAc (4 x 15 mL), and washed 
with NaHCO3 (3 x 20 mL), and H2O (1 x 15 mL). The organic phase was dried (MgSO4), and 
evaporated under reduced pressure. The crude product was purified by column 
chromatography (1:1.5 EtOAc–hexane) to yield 1.00 g (87%) of 5 as a yellow amorphous 
product. [α]D = +7 (c 0.33, CHCl3); Rf : 0.55 (1:1 EtOAc–hexane); 
1
H NMR (CDCl3, 360 
MHz)  (ppm) 10.74 (1H, s, NH), 9.19 (1H, s, NH), 8.04-7.18 (26H, m, Ar, CH=N), 6.09-
5.99 (2H, m, H-2 and/or H-3 and/or H-4), 5.76 (1H, 1 pt, J = 9.3 Hz, H-2 or H-3 or H-4), 4.66 
(1H, dd, J5,6a = 2.4 Hz, J6a,6b = 12.2 Hz, H-6a), 4.54 (1H, dd, J1, CH=N = 4.0 Hz, J1,2 = 9.2 Hz, 
H-1), 4.49 (1H, dd, J5,6b = 5.3 Hz, H-6b), 4.26-4.22 (1H, m, H-5). 
13
C NMR (CDCl3, 360 
MHz)  (ppm) 176.0 (CS), 166.0, 165.2, 165.2, 164.9 (CO), 138.1 (CH=N), 137.6-124.5 (Ar), 
76.0, 76.1, 74.1, 69.33, 69.1 (C-1–C-5), 62.8 (C-6). Anal. Calcd. for C42H35N3O9S (757.81): 
C, 66.57, H, 4.66; N, 5.54; S, 4.23. Found: C, 66.63; H, 4.72; N, 5.58; S, 4.29. 
 
4.5. 2-Phenylamino-5-(2,3,4,6-tetra-O-benzoyl--D-glucopyranosyl)-1,3,4-oxadiazole (10) 
Semicarbazone 3 (0.20 g, 0.27 mmol) was dissolved in glacial AcOH (3 mL). Then Pb(OAc)4 
(0.18 g, 0.40 mmol) was added, and the mixture was stirred and heated at 70 °C. The reaction 
was monitored by TLC (1:2 EtOAc–hexane). When the reaction was complete, the reaction 
mixture was diluted with H2O (15 mL), and extracted with EtOAc (3 x 6ml). The organic 





































































purified by column chromatography (1:2 EtOAc–hexane) to yield 90 mg (45%) of 10 as a 
white amorphous product. [α]D = –17 (c 0.21, CHCl3); Rf : 0.41 (1:2 EtOAc–hexane); 
1
H NMR 
(CDCl3, 360 MHz)  (ppm) 8.87 (1H, s, NH), 8.02-7.00 (25H, m, Ar), 6.08, 5.93, 5.83 (3H, 3 
pt, J = 9.5, 9.7 Hz in each, H-2, H-3, H-4), 5.13 (1H, d, J1,2 = 9.9 Hz, H-1), 4.65 (1H, dd, J5,6a 
= 2.0 Hz, J6a,6b = 12.4 Hz, H-6a), 4.51 (1H, dd, J5,6b = 5.2 Hz, H-6b) 4.40-4.30 (1H, m, H-5). 
13
C NMR (CDCl3, 360 MHz)  (ppm) 166.1, 165.7, 165.1, 164.9 (CO), 161.2, 154.8 (C-
oxadiazole), 137.4-117.8 (Ar), 76.8, 73.6, 71.9, 70.1, 69.1 (C-1–C-5), 63.0 (C-6). Anal. 
Calcd. for C42H33N3O10 (739.73): C, 68.19, H, 4.50; N, 5.68. Found: C, 68.25; H, 4.59; N, 
5.61. 
 
4.6. General procedure I for the synthesis of O-perbenzoylated 4-acyl-[C-(-D-
glucopyranosyl)formaldehyde]semicarbazones  
C-(2,3,4,6-Tetra-O-benzoyl--D-glucopyranosyl)formaldehyde semicarbazone18 (2, 0.10 g, 
0.15 mmol) was dissolved in dry CH2Cl2 (5 mL), and then Et3N (0.063 mL, 0.45 mmol) and 
an RCOCl (0.45 mmol) were added. The mixture was stirred and heated at 40 °C. The 
reaction was monitored by TLC (1:1 EtOAc–hexane). When the reaction was complete, the 




From 2 (0.19 g, 0.29 mmol) and AcCl (62 L, 0.87 mmol) according to General procedure I 
(Section 4.6.). Purified by column chromatography (1:1.5 EtOAc–hexane) to yield 91 mg 
(47%) of 12 as a yellow amorphous product. [α]D = +8 (c 0.35, CHCl3); Rf : 0.37 (1:1 EtOAc–
hexane); 
1
H NMR (CDCl3, 360 MHz)  (ppm) 9.83 (1H, s, NH), 8.10-7.80 (8H, m, Ar), 7.58-





































































H-4), 4.65 (1H, dd, J5,6a = 1.8 Hz, J6a,6b = 12.2 Hz, H-6a), 4.52-4.37 (2H, m, H-1, H-6b), 4.28-
4.17 (1H, m, H-5), 1.91 (3H, s, CH3). 
13
C NMR (CDCl3, 360 MHz)  (ppm) 173.8, 166.1, 
165.8, 165.3, 165.1, 158.4 (CO, NHCO, NHCONH), 140.5 (CH=N), 133.4-128.2 (Ar), 77.7, 
76.2, 73.7, 70.2, 69.3 (C-1–C-5), 63.0 (C-6), 19.7 (CH3). Anal. Calcd. for C38H33N3O11 




From 2 (0.10 g, 0.15 mmol) and BzCl (53 L, 0.45 mmol) according to General procedure I 
(Section 4.6.). Purified by column chromatography (1:1.5 EtOAc–hexane) to yield 81 mg 
(70%) of 13 as a yellow amorphous product. [α]D = –61 (c 0.18, CHCl3); Rf : 0.51 (1:1 
EtOAc–hexane); 1H NMR (CD3CN, 360 MHz)  (ppm) 10.28 (1H, bs, NH), 8.06-7.30 (27H, 
m, Ar, CH=N, NH), 6.06, 5.80, 5.73 (3H, 3 pt, J = 9.5, 9.8 Hz in each, H-2, H-3, H-4), 4.70-
4.65 (1H, m, H-5), 4.59 (2H, dd, J5,6a = 2.4 Hz, J6a,6b = 12.5 Hz, H-6a), 4.53 (1H, dd, J5,6b = 
4.1 Hz, H-6b), 4.42 (1H, d, J1,2 = 9.1 Hz, H-1). 
13
C NMR (CD3CN, 360 MHz)  (ppm) 166.7, 
166.4, 166.1, 166.0, 164.5 (CO, NHCO, NHCONH), 145.9 (CH=N) 134.5-118.2 (Ar), 78.6, 
76.5, 75.1, 71.5, 70.0 (C-1–C-5), 63.7 (C-6). Anal. Calcd. for C43H35N3O11 (769.75): C, 
67.09, H, 4.58; N, 5.46. Found: C, 67.01; H, 4.50; N, 5.55. 
 
4.6.3. 4-(2-Naphthoyl)-[C-(2,3,4,6-tetra-O-benzoyl--D-
glucopyranosyl)formaldehyde]semicarbazone (14)  
From 2 (0.20 g, 0.30 mmol) and 2-naphthoyl chloride (172 mg, 0.90 mmol) according to 
General procedure I (Section 4.6.). Purified by column chromatography (1:3,5 EtOAc–
toluene) to yield 123 mg (50%) of 14 as a yellow amorphous product. [α]D = –134 (c 0.16, 
CHCl3); Rf: 0.43 (1:3.5 EtOAc–toluene); 
1





































































NH), 8.18-7.23 (29H, m, Ar, CH=N, NH), 6.06, 5.77, 5.65 (3H, 3 pt, J = 8.7 Hz, 9.3 Hz in 
each, H-2, H-3, H-4), 4.73-4.58 (2H, m, H-1, H-6a), 4.48 (1H, dd, J5,6b = 4.9 Hz, J6a,6b = 12.1 
Hz, H-6b), 4.32-4.19 (1H, m, H-5). 
13
C NMR (CDCl3, 360 MHz)  (ppm) 166.1, 165.7, 
165.3, 164.3 (CO, NHCO, NHCONH), 145.1 (CH=N), 134.8-123.8 (Ar), 78.5, 76.3, 73.6, 
70.8, 69.4 (C-1–C-5), 63.2 (C-6). Anal. Calcd. for C47H37N3O11 (819.81): C, 68.86, H, 4.55; 
N, 5.13. Found: C, 68.97; H, 4.65; N, 5.20. 
 
4.6.4. 4-(4-tert-Butylbenzoyl)-[C-(2,3,4,6-tetra-O-benzoyl--D-
glucopyranosyl)formaldehyde]semicarbazone (15)  
From 2 (0.10 g, 0.15 mmol) and 4-tert-butylbenzoyl chloride (88 L, 0.45 mmol) according 
to General procedure I (Section 4.6.). Purified by column chromatography (1:2 EtOAc–
hexane) to yield 68 mg (55%) of 15 as a yellow amorphous product. [α]D = +41 (c 0.52, 
CHCl3); Rf : 0.27 (1:2 EtOAc–hexane); 
1
H NMR (CDCl3, 360 MHz)  (ppm) 9.66 (1H, bs, 
NH), 8.01-7.21 (26H, m, Ar, CH=N, NH), 6.06, 5.77, 5.64 (3H, 3 pt, J = 8.6, 9.3 Hz in each, 
H-2, H-3, H-4), 4.76-4.56 (2H, m, H-1, H-6a), 4.49 (1H, dd, J5,6b = 4.9 Hz, J6a,6b = 12.1 Hz, 
H-6b), 4.32-4.18 (1H, m, H-5), 1.26 (9H, s, CH3). 
13
C NMR (CDCl3, 360 MHz)  (ppm) 
166.0, 165.9, 165.6, 165.2 (CO, NHCO, NHCONH), 144.6 (CH=N), 155.4, 133.4-125.2 (Ar), 
78.6, 76.2, 73.6, 70.8, 69.3 (C-1–C-5), 63.2 (C-6), 34.7 (CtBu), 30.9 (CH3). Anal. Calcd. for 
C47H43N3O11 (825.86): C, 68.35, H, 5.25; N, 5.09. Found: C, 68.44; H, 5.36; N, 5.16. 
 
4.7. General procedure II for the synthesis of 4-acyl-2-acylamino-5-(2,3,4,6-tetra-O-
benzoyl--D-glucopyranosyl)-Δ2-1,3,4-thiadiazolines  
C-(2,3,4,6-Tetra-O-benzoyl--D-glucopyranosyl)formaldehyde thiosemicarbazone (4, 0.10 g, 
0.14 mmol) was dissolved in dry pyridine (5 mL) and then RCOCl (0.44 mmol) was added. 





































































EtOAc–hexane). When the reaction was complete, the solvent was evaporated, and the 
residue was purified by column chromatography. 
 
4.7.1. 2-Acetamido-4-acetyl-5-(2,3,4,6-tetra-O-benzoyl--D-glucopyranosyl)-Δ2-1,3,4-
thiadiazoline (16)  
From 4 (0.20 g, 0.28 mmol) and AcCl (60 L, 0.84 mmol) according to General procedure II 
(Section 4.7.). Purified by column chromatography (1:2 EtOAc–toluene) to yield 170 mg 
(77%) of 16 as a white amorphous product. [α]D = –178 (c 0.35, CHCl3); Rf : 0.30 (1:2 
EtOAc–toluene); ESI-MS (positive mode) m/z: 766.25 [M+H]+. Anal. Calcd. for 
C40H35N3O11S (765.78): C, 62.74, H, 4.61; N, 5.49; S, 4.19. Found: C, 62.71; H, 4.65; N, 




H NMR (CDCl3, 360 MHz)  (ppm) 9.43 (1H, s, NH), 8.10-7.11 (20H, m, Ar), 
6.05-5.96 (2H, m, H-2 or H-3 or H-4, CH-thiadiazoline), 5.68, 5,56 (2H, 2 pt, J = 9.8 Hz in 
each, H-2 and/or H-3 and/or H-4), 4.53-4.42 (3H, m, H-6a, H-6b, H-1), 4.15-4.08 (1H, m, H-
5), 1.99, 1.93 (6H, 2 s, CH3). 
13
C NMR (CDCl3, 360 MHz)  (ppm) 169.0, 166.0, 165.6, 165.0 
(CO, NHCO), 147.4 (Cq-thiadiazoline), 133.6-125.1 (Ar), 76.0, 75.2, 73.5, 69.1, 66.3 (C-1–
C-5), 69.1 (CH-thiadiazoline), 62.4 (C-6), 22.6, 21.5 (CH3). 
minor isomer: 
1
H NMR (CDCl3, 360 MHz)  (ppm) 9.14 (1H, s, NH), 5.84, 5.43 (2H, 2 pt, J 
= 9.5, 9.7 Hz in each, H-2 and/or H-3 and/or H-4).  
 
4.7.2. 2-Benzamido-4-benzoyl-5-(2,3,4,6-tetra-O-benzoyl--D-glucopyranosyl)-Δ2-1,3,4-
thiadiazoline (17)  
From 4 (0.50 g, 0.74 mmol) and BzCl (258 L, 2.22 mmol) according to General procedure II 





































































(62%) of 17 as a yellow amorphous product. [α]D = –295 (c 0.16, CHCl3); Rf : 0.34 (1:2 
EtOAc–hexane). ESI-MS (positive mode) m/z: 890.33 [M+H]+. Anal. Calcd. for 
C50H39N3O11S (889.92): C, 67.48, H, 4.42; N, 4.72; S, 3.60. Found: C, 67.42; H, 4.45; N, 




H NMR (CDCl3, 400 MHz)  (ppm) 9.26 (1H, s, NH) 8.05-7.10 (30H, m, Ar), 
6.34 (1H, s, CH-thiadiazoline), 6.02 (1H, pt, J = 9.5 Hz, H-2 or H-3 or H-4), 5.72-5.60 (2H, 
m, H-2 and/or H-3 and/or H-4), 4.62 (1H, d, J1,2 = 9.7 Hz, H-1), 4.54 (1H, dd, J5,6a = 5.3 Hz, 
J6a,6b = 12.3 Hz, H-6a), 4.48 (1H, dd, J5,6b = 1.9 Hz, H-6b), 4.17-4.11 (1H, m, H-5). 
13
C NMR 
(CDCl3, 400 MHz)  (ppm) 166.6, 166.2, 165.7, 165.7, 165.1, 165.0 (CO, NHCO), 148.4 
(Cq-thiadiazoline) 133.7-127.3 (Ar), 76.5, 75.9, 73.7, 69.2, 67.7 (C-1–C-5), 69.1 (CH-
thiadiazoline), 62.6 (C-6).  
minor isomer: 
1
H NMR (CDCl3, 400 MHz)  (ppm) 9.10 (1H, s, NH), 6.63 (1H, s, CH-
thiadiazoline), 6.09, 5.90 (2H, 2 pt, J = 9.5 Hz in each, H-2 and/or H-3 and/or H-4), 4.72 (1H, 
d, J1,2 = 9.1 Hz, H-1), 4.67 (1H, dd, J5,6a = 2.3 Hz, J6a,6b = 12.4 Hz, H-6a), 4.41 (1H, dd, J5,6b = 
4.9 Hz, H-6b), 4.26-4.20 (1H, m, H-5). 
13
C NMR (CDCl3, 400 MHz)  (ppm) 76.1, 74.8, 68.6 
(C-1–C-5), 60.3 (C-6).  
 
4.7.3. 2-(2-Naphthamido)-4-(2-naphtoyl)-5-(2,3,4,6-tetra-O-benzoyl--D-glucopyranosyl)-
Δ2-1,3,4-thiadiazoline (18)  
From 4 (0.50 g, 0.74 mmol) and 2-naphthoyl chloride (423 mg, 2.22 mmol) according to 
General procedure II (Section 4.7.). Purified by column chromatography (1:2 EtOAc–hexane) 
to yield 450 mg (62%) of 18 as a yellow amorphous product. [α]D = –318 (c 0.16, CHCl3); Rf : 





































































C58H43N3O11S (989.26): C, 70.36, H, 4.38; N, 4.24; S, 3.24. Found: C, 70.32; H, 4.36; N, 




H NMR (CDCl3, 400 MHz)  (ppm) 9.30 (1H, s, NH) 8.36-6.84 (34H, m, Ar), 
6.36 (1H, d, CH-thiadiazoline), 5.96 (1H, pt, J = 9.5 Hz, H-2 or H-3 or H-4), 5.70-5.61 (2H, 
m, H-2 and/or H-3 and/or H-4), 4.60 (1H, dd, J1,CH = 1.4 Hz, J1,2 = 9.9 Hz, H-1), 4.52 (1H, dd, 
J6a,6b = 12.2 Hz, H-6a,), 4.46 (1H, dd, H-6b), 3.97 (1H, ddd, J5,6b = 2.7 Hz, J5,6a = 4.9 Hz, J4,5 
= 9.7 Hz, H-5). 
13
C NMR (CDCl3, 400 MHz)  (ppm) 169.7, 166.5, 166.3, 165.8, 165.7, 
165.0 (CO, NHCO), 148.1 (Cq-thiadiazoline), 135.3-123.5 (Ar), 76.4, 75.8, 73.7, 69.1, 68.0 
(C-1–C-5), 69.1 (CH-thiadiazoline), 62.5 (C-6).  
minor isomer: 
1
H NMR (CDCl3, 400 MHz)  (ppm) 6.68 (1H, d, CH-thiadiazoline), 6.13, 
5.89 (2H, 2 pt, J = 9.5 Hz in each, H-2 and/or H-3 and/or H-4), 4.76 (1H, dd, J1,CH =2.5 Hz, 
J1,2 =9.8 Hz, H-1), 4.65 (1H, dd, J6a,6b =12.3 Hz, H-6a), 4.19 (1H, ddd, J5,6a =2.8 Hz, J5,6b =4.6 
Hz, J4,5 = 9.6 Hz, H-5). 
13
C NMR (CDCl3, 400 MHz)  (ppm) 167.3, 166.2, 165.4, 164.9 (CO, 
NHCO), 148.7 (Cq-thiadiazoline), 76.1, 75.4, 74.8, 68.5, 67.8 (C-1–C-5), 63.0 (C-6). 
 
4.7.4. 2-(4-tert-Butylbenzamido)-4-(4-tert-butylbenzoyl)-5-(2,3,4,6-tetra-O-benzoyl--D-
glucopyranosyl)-Δ2-1,3,4-thiadiazoline (19)  
From 4 (0.15 g, 0.22 mmol) and 4-tert-butylbenzoyl chloride (129 L, 0.66 mmol) according 
to General procedure II (Section 4.7.). Purified by column chromatography (1:4 EtOAc–
hexane) to yield 83 mg (38%) of 19 as a yellow amorphous product. [α]D = –378 (c 0.18, 
CHCl3); Rf : 0.48 (1:2 EtOAc–hexane); 
1
H NMR (CDCl3, 360 MHz)  (ppm) 8.71 (1H, s, 
NH), 8.01-7.14 (28H, m, Ar), 6.36 (1H, d, J = 1.4 Hz, CH-thiadiazoline), 6.01, 5.65, 5.64 
(3H, 3 pt, J = 9.5 Hz in each, H-2, H-3, H-4), 4.64-4.55 (2H, m, H-6a, H-1), 4.42 (1H, dd, 





































































(9H, bs, CH3), 1.31 (9H, s, CH3). 
13
C NMR (CDCl3, 360 MHz)  (ppm) 166.4, 166.3, 165.8, 
165.8, 165.2, 164.7 (CO, NHCO), 156.9, 154.3 (Cq-phenyl), 145.9 (Cq-thiadiazoline), 133.7-
124.7 (Ar), 76.6, 76.0, 73.8, 69.3, 67.8, (C-1–C-5), 69.1 (CH-thiadiazoline), 62.8 (C-6), 35.2, 
34.9 (Cq), 31.2, 31.1 (CH3). ESI-MS (positive mode) m/z: 1002.33 [M+H]
+
. Anal. Calcd. for 
C58H55N3O11S (1002.14): C, 69.51, H, 5.53; N, 4.19; S, 3.20. Found: C, 69.54; H, 5.56; N, 
4.16; S, 3.25. 
 
4.8. General procedure III for the synthesis of 2-acylamino-5-(2,3,4,6-tetra-O-benzoyl--
D-glucopyranosyl)-1,3,4-oxadiazoles and -thiadiazoles  
A 4-acyl-[C-(2,3,4,6-tetra-O-benzoyl--D-glucopyranosyl)formaldehyde]semicarbazone (12-
15, 0.03 mmol) or a 2-acylamino-4-acyl-5-(2,3,4,6-tetra-O-benzoyl--D-glucopyranosyl)-
1,3,4-thiadiazoline (16-19, 0.03 mmol) was dissolved in CH2Cl2 (1 mL). Then PIDA (1.1 
equiv.) was added, and the mixture was stirred at room temperature. The reaction was 
monitored by TLC (1:1 EtOAc–hexane). When the reaction was complete, the solvent was 
evaporated and the residue was purified by column chromatography.  
 
4.8.1. 2-Acetamido-5-(2,3,4,6-tetra-O-benzoyl--D-glucopyranosyl)-1,3,4-oxadiazole (20) 
From 12 (0.16 g, 0.23 mmol) according to General procedure III (Section 4.8.). Purified by 
column chromatography (1:3 EtOAc–hexane) to yield 81 mg (50%) of 20 as a white 
amorphous product. [α]D = –2 (c 0.25, CHCl3); Rf : 0.38 (1:3 EtOAc–toluene); 
1
H NMR 
(CDCl3, 360 MHz)  (ppm) 8.03-7.22 (21H, m, Ar, NH), 6.08, 5.86, 5.84 (3H, 3 pt, J = 9.7 
Hz in each H-2, H-3, H-4), 5.18 (1H d, J1,2 = 9.8 Hz, H-1), 4.71-4.60 (1H, dd, J5,6a < 1 Hz, H-
6a), 4.52 (1H, dd, J5,6b = 4.3 Hz, J6a,6b = 12.1 Hz, H-6b), 4.40-4.30 (1H, m, H-5), 2.53 (1H, s, 
CH3). 
13
C NMR (CDCl3, 360 MHz)  (ppm) 166.0, 165.6, 165.2, 165.0, 164.8, 160.9 (CO, 





































































11.0 (CH3). Anal. Calcd. for C38H31N3O11 (705.67): C, 64.68, H, 4.43; N, 5.95. Found: C, 
64.60; H, 4.51; N, 5.86. 
 
4.8.2. 2-Benzamido-5-(2,3,4,6-tetra-O-benzoyl--D-glucopyranosyl)-1,3,4-oxadiazole (21)  
From 13 (0.084 g, 0.11 mmol) according to General procedure III (Section 4.8.). Purified by 
column chromatography (1:3 EtOAc–hexane) to yield 70 mg (57%) of 21 as a white 
amorphous product. [α]D = –205 (c 0.4, CHCl3); Rf : 0.68 (1:1 EtOAc–hexane); 
1
H NMR 
(CDCl3, 360 MHz)  (ppm) 8.06-7.26 (26H, m, Ar, NH), 6.11, 6.02, 5.88 (3H, 3 pt, J = 9.5, 
9.8 Hz in each H-2, H-3, H-4), 5.28 (1H d, J1,2 = 9.8 Hz, H-1), 4.71 (1H, dd, J6a,6b = 12.4 Hz, 
H-6a), 4.54 (1H, dd, H-6b) 4.39 (1H, ddd, J5,6a = 2.4 Hz, J5,6b = 5.2 Hz, J4,5 = 9.4 Hz , H-5). 
13
C NMR (CDCl3, 360 MHz)  (ppm) 166.0, 165.9, 165.6, 165.1, 164.8, 160.9 (CO, NHCO, 
C-oxadiazole), 133.5-123.3 (Ar), 77.0, 73.5, 71.8, 70.2, 69.0 (C-1–C-5), 62.9 (C-6). Anal. 





From 14 (0.28 g, 0.34 mmol) according to General procedure III (Section 4.8.). Purified by 
column chromatography (1:6 EtOAc–toluene) to yield 192 mg (69%) of 22 as a yellow 
amorphous product. [α]D = –121 (c 0.16, CHCl3); Rf.: 0.58 (1:3.5 EtOAc-toluene); 
1
H NMR 
(CDCl3, 360 MHz)  (ppm) 8.52 (1H, s, NH), 8.11-7.10 (27H, m, Ar), 6.18, 6.11, 5.95 (3H, 3 
pt, J = 9.7 Hz in each, H-2, H-3 , H-4), 5.27 (1H, d, J1,2 = 9.5 Hz, H-1), 4.70 (1H, dd, J6a,6b = 
12.4 Hz, H-6a), 4.54 (1H, dd, H-6b) 4.39 (1H, ddd, J5,6a = 2.7 Hz, J5,6b = 4.3 Hz, J4,5 = 9.5 Hz, 
H-5). 
13
C NMR (CDCl3, 360 MHz)  (ppm) 166.0, 165.9, 165.6, 164.8, 161.1 (CO, NHCO, 










































































From 15 (0.09 g, 0.11 mmol) according to General procedure III (Section 4.8.). Purified by 
column chromatography (1:3 EtOAc–hexane) to yield 80 mg (60%) of 23 as a colourless 
amorphous product. [α]D = –82 (c 1.50, CHCl3); Rf : 0.29 (1:3 EtOAc–hexane); 
1
H NMR 
(CDCl3, 360 MHz)  (ppm) 8.05-7.20 (25H, m, Ar, NH), 6.11, 6.02 , 5.88 (3H, 3 pt, J = 9.5, 
9.7 Hz in each, H-2, H-3, H-4), 5.28 (1H, d, J1,2 = 9.7 Hz, H-1), 4.70 (1H, dd, J6a,6b = 12.4 Hz 
, H-6a), 4.54 (1H, dd, H-6b), 4.40 (1H, ddd, J5,6a = 2.3 Hz, J5,6b = 5.3 Hz, J4,5 = 9.7 Hz, H-5), 
1.34 (9H, s, CH3). 
13
C NMR (CDCl3, 360 MHz)  (ppm) 166.0, 165.9, 165.6, 165.1, 164.8, 
161.1 (CO, NHCO, C-oxadiazole), 155.6, 133.5-120.5 (Ar), 77.0, 73.6, 71.8, 70.2, 69.1 (C-1–
C-5), 63.0 (C-6), 35.0 (Cq-tBu), 31.0 (CH3). Anal. Calcd. for C47H41N3O11 (823.84): C, 68.52, 
H, 5.02; N, 5.10. Found: C, 68.61; H, 5.11; N, 5.18. 
 
4.8.5. 2-Acetamido-5-(2,3,4,6-tetra-O-benzoyl--D-glucopyranosyl)-1,3,4-thiadiazole (24) 
From 16 (0.17 g, 0.22 mmol) according to General procedure III (Section 4.8.). Purified by 
column chromatography (1:2 EtOAc–toluene) to yield 106 mg (67%) of 24 as a white 
amorphous product. [α]D = –81 (c 0.25, CHCl3); Rf : 0.42 (1:2 EtOAc–toluene); 
1
H NMR 
(CDCl3, 360 MHz)  (ppm) 8.09-7.13 (21H, m, Ar, NH), 6.09, 5.81, 5.74 (3H, 3 pt, J = 9.6, 
9.8 Hz in each, H-2, H-3, H-4), 5.25 (1H, d, J1,2 = 9.6 Hz, H-1), 4.70 (1H, dd, J6a,6b = 12.3 Hz, 
H-6a), 4.53 (1H, dd, H-6b), 4.36 (1H, ddd, J5,6a = 3.0 Hz, J5,6b = 4.8 Hz, J4,5 = 9.5 Hz, H-5), 
1.82 (3H, s, CH3). 
13
C NMR (CDCl3, 360 MHz)  (ppm) 168.8, 166.1, 165.7, 165.1, 164.7 





































































(C-6). ESI-MS (positive mode) m/z: 722.33 [M+H]
+
. Anal. Calcd. for C38H31N3O10S 
(721.76): C, 63.24, H, 4.33; N, 5.82; S,4.44. Found: C, 63.21; H, 4.35; N, 5.84; S, 4.41. 
 
4.8.6. 2-Benzamido-5-(2,3,4,6-tetra-O-benzoyl--D-glucopyranosyl)-1,3,4-thiadiazole (25) 
From 17 (0.09 g, 0.10 mmol) according to General procedure III (Section 4.8.). Purified by 
column chromatography (1:3 EtOAc–hexane) to yield 54 mg (68%) of 25 as a white 
amorphous product. [α]D = –111 (c 0.20, CHCl3); Rf : 0.21 (1:2 EtOAc–hexane); 
1
H NMR 
(CDCl3, 360 MHz)  (ppm) 8.20-7.26 (26H, m, Ar, NH), 6.12, 5.86, 5.77 (3H, 3 pt, J = 9.5, 
9.8 Hz in each, H-2, H-3, H-4), 5.32 (1H, d, J1,2 = 9.7 Hz, H-1), 4.70 (1H, dd, J6a,6b = 12.4 Hz 
, H-6a), 4.55 (1H, dd, H-6b) 4.40 (1H, ddd, J5,6a = 2.7 Hz, J5,6b = 5.0 Hz, J4,5 = 9.7 Hz , H-5). 
13
C NMR (CDCl3, 360 MHz)  (ppm) 166.2, 165.7, 165.1, 165.0, 164.9, 162.5, 161.1 (CO, 
NHCO, C-thiadiazole), 133.3-128.3 (Ar), 77.0, 76.3, 73.6, 72.2, 69.2, (C-1–C-5), 63.1 (C-6). 
Anal. Calcd. for C43H33N3O10S (783.8): C, 65.89, H, 4.24; N, 5.36; S,4.09. Found: C, 65.94; 




From 18 (0.20 g, 0.20 mmol) according to General procedure III (Section 4.8.). Purified by 
column chromatography (1:6 EtOAc–toluene) to yield 100 mg (59%) of 26 as a yellow 
amorphous product. [α]D= –205 (c 0.16, CHCl3); Rf : 0.39 (1:6 EtOAc–toluene); 
1
H NMR 
(CDCl3, 360 MHz)  (ppm) 8.71 (s, 1H, NH), 8.12-7.11 (27H, m, Ar), 6.15, 5.91, 5.80 (3H, 
3pt, J = 9.6 Hz in each, H-2, H-3, H-4), 5.35 (1H, d, J1,2 = 9.7 Hz, H-1), 4.70 (1H, dd, J6a,6b = 
12.3 Hz , H-6a), 4.57 (1H, dd, H-6b), 4.41 (1H, ddd, J5,6a = 2.0 Hz, J5,6b = 4.9 Hz, J4,5 = 9.4 
Hz, H-5). 
13
C NMR (CDCl3, 360 MHz)  (ppm) 166.1, 165.7, 165.2, 165.1, 165.0, 162.5, 





































































63.1 (C-6). ESI-MS (positive mode) m/z: 834.33 [M+H]
+
. Anal. Calcd. for C47H35N3O10S 




From 19 (0.17 g, 0.17 mmol) according to General procedure III (Section 4.8.). Purified by 
column chromatography (1:3 EtOAc–hexane) to yield 120 mg (84%) of 27 as a white 
amorphous product. [α]D = –179 (c 0.20, CHCl3); Rf : 0.20 (1:3 EtOAc–hexane); 
1
H NMR 
(CDCl3, 360 MHz)  (ppm) 8.05-7.22 (25H, m, Ar, NH), 6.12, 5.86, 5.80 (3H, 3 pt, J = 9.5, 
9.7 Hz in each, H-2, H-3, H-4), 5.31 (1H, d, J1,2 = 9.6 Hz, H-1), 4.68 (1H, dd, J5,6a < 1 Hz, 
J6a,6b = 12.2 Hz , H-6a), 4.54 (1H, dd, J5,6b = 5.0 Hz, H-6b), 4.43-4.35 (1H, m, H-5), 1.38 (9H, 
s, CH3). 
13
C NMR (CDCl3, 360 MHz)  (ppm) 166.1, 165.8, 165.2, 165.0, 164.8, 161.8, 160.9 
(CO, NHCO, C-thiadiazole), 156.9, 133.5-125.8 (Ar), 76.9, 76.3, 73.7, 72.2, 69.4 (C-1–C-5), 
63.2 (C-6), 31.9 (Cq-tBu), 31.1 (CH3). ESI-MS (positive mode) m/z: 840.42 [M+H]
+
. Anal. 
Calcd. for C47H41N3O10S (839.91): C, 67.21, H, 4.92; N, 5.00; S, 3.82. Found: C, 67.31; H, 
4.83; N, 5.09; S, 3.91. 
 
4.9. Preparation for the test compounds  
4.9.1. General procedure IV for the Zemplén debenzoylation 
An O-perbenzoylated compound (100 mg) was dissolved in dry MeOH (1 mL) and a solution 
of NaOMe (1 M in MeOH) was added to the solution in a catalytic amount. The reaction 
mixture was kept at rt. When the reaction was complete (TLC, 7:3 CHCl3–MeOH) the 
solution was neutralized with a cation exchange resin Amberlyst 15 (H
+
 form). The resin was 
filtered off with suction, the filtrate was evaporated under reduced pressure. The crude 






































































4.9.2. General procedure V for the removal of O-benzoyl protecting groups 
An O-perbenzoylated compound (100 mg) was dissolved in dry MeOH (14 mL) and LiOH 
(16 equiv.) was added. The reaction mixture was stirred at 0 °C. When the reaction was 
complete (TLC, 7:3 CHCl3–MeOH) the solution was neutralized with a cation exchange resin 
Amberlyst 15 (H
+
 form). After filtration and removal of the solvent, the residue was purified 
by column chromatography. 
 
4.9.3. C-(-D-glucopyranosyl)formaldehyde semicarbazone (6) 
From 2 (0.17 g, 0.26 mmol) according to General procedure IV (Section 4.9.1.). Purified by 
column chromatography (8:5 CHCl3–methanol) to yield 40 mg (63%) of 6 as a white 
amorphous product. [α]D = +32 (c 0.30, DMSO); Rf : 0.17 (2:1 CHCl3–methanol); 
1
H NMR 
(MeOD, 360 MHz)  (ppm) 7.19 (1H, s, CH=N), 3.88-3.72 (2H, m, H-1, H-2 or H-3 or H-4), 
3.70-3.52 (1H, m, H-6a), 3.50-3.22 (4H, m, H-2 and/or H-3 and/or H-4, H-5, H-6b). 
13
C NMR 
(MeOD, 360 MHz)  (ppm) 160.1 (NHCONH), 143.2 (CH=N), 81.8, 80.2, 79.4, 73.4, 71.4 
(C-1–C-5), 62.7 (C-6). Anal. Calcd. for C84H15N3O6 (249.22): C, 38.55, H, 6.07; N, 16.86. 
Found: C, 38.63; H, 6.12; N, 16.93. 
 
4.9.4. 4-Phenyl-[C-(-D-glucopyranosyl)formaldehyde]semicarbazone (7) 
From 3 (0.20 g, 0.27 mmol) according to General procedure IV (Section 4.9.1.). Purified by 
column chromatography (4:1 CHCl3–methanol) to yield 42 mg (48%) of 7 as a white 
amorphous product. [α]D = +52 (c 0.43, DMSO); Rf : 0.23 (4:1 CHCl3–methanol); 
1
H NMR 
(MeOD, 360 MHz)  (ppm) 7.46 (2H, d, J = 7.9 Hz, Ar), 7.30-7.17 (3H, m, Ar, CH=N), 7.01 
(1H, t, J = 7.3 Hz, Ar), 3.91-3.79 (2H, m, H-1, H-2 or H-3 or H-4), 3.65 (1H, dd, J5,6a = 4.5 







































































NMR (MeOD, 360 MHz)  (ppm) 155.9 (NHCONH), 143.3 (CH=N), 139.7, 129.8, 124.5, 
121.3 (Ar), 82.0, 80.2, 79.5, 73.5, 71.5 (C-1–C-5), 62.8 (C-6). Anal. Calcd. for C14H19N3O6 
(325.32): C, 51.69, H, 5.89; N, 12.92. Found: C, 51.79; H, 5.98; N, 12.85. 
 
4.9.5. C-(-D-glucopyranosyl)formaldehyde thiosemicarbazone(8) 
From 4 (0.16 g, 0.24 mmol) according to General procedure V (Section 4.9.2.). Purified by 
column chromatography (3:1 CHCl3–methanol) to yield 60 mg (95%) of 8 as a white 
amorphous product. [α]D = +6 (c 2.00, DMSO); Rf : 0.24 (3:1 CHCl3–methanol); 
1
H NMR 
(MeOD, 360 MHz)  (ppm) 7.39 (1H, s, CH=N), 3.92-3.81 (2H, m, H-1, H-2 or H-3 or H-4), 
3.68 (1H, dd, J5,6a = 3.1 Hz, J6a,6b = 10.9 Hz, H-6a), 3.52-3.32 (4H, m, H-2 and/or H-3 and/or 
H-4, H-5, H-6b). 
13
C NMR (MeOD, 360 MHz)  (ppm) 180.0 (NHCSNH), 145.5 (CH=N), 
81.7, 79.8, 79.0, 73.2, 71.4 (C-1–C-5), 62.7 (C-6). Anal. Calcd. for C8H15N3O5S (265.29): C, 
36.22, H, 5.70; N, 15.84; S, 12.09. Found: C, 36.12; H, 5.81; N, 15.92; S, 12.17. 
 
4.9.6. 4-Phenyl-[C-(-D-glucopyranosyl)formaldehyde]thiosemicarbazone (9) 
From 5 (0.20 g, 0.26 mmol) according to General procedure V (Section 4.9.2.). Purified by 
column chromatography (7:1 CHCl3–methanol) to yield 70 mg (77%) of 9 as a yellow 
amorphous product. [α]D = +33 (c 0.13, MeOH); Rf : 0.40 (3:1 CHCl3–methanol); 
1
H NMR 
(MeOD, 360 MHz)  (ppm) 7.61 (2H, d, J = 7.8 Hz, Ar), 7.42-7.30 (3H, m, Ar, CH=N), 7.21 
(1H, t, J = 7.4 Hz, Ar), 3.97-3.82 (2H, m, H-1, H-2 or H-3 or H-4), 3.71 (1H, dd, J5,6a = 4.8 
Hz, J6a,6b = 11.8 Hz, H-6a), 3.48-3.33 (4H, m, H-2 and/or H-3 and/or H-4, H-5, H-6b). 
13
C 
NMR (MeOD, 360 MHz)  (ppm) 178.3 (NHCSNH), 144.7 (CH=N), 140.1, 129.4, 126.8, 
126.2 (Ar), 82.0, 80.1, 79.5, 73.4, 71.5 (C-1–C-5), 62.8 (C-6). Anal. Calcd. for C13H19N3O5S 






































































4.9.7. 2-Phenylamino-5-(-D-glucopyranosyl)-1,3,4-oxadiazole (11) 
From 10 (0.16 g, 0.22 mmol) according to General procedure IV (Section 4.9.1.). Purified by 
column chromatography (7:1 CHCl3–methanol) to yield 68 mg (97%) of 11 as a white 
amorphous product. [α]D = +14 (c 0.21, DMSO); Rf : 0.24 (7:1 CHCl3–methanol); 
1
H NMR 
(MeOD, 360 MHz)  (ppm) 7.49 (2H, d, J = 8.0 Hz, Ar), 7.33 (2H, t, J = 7.6 Hz, Ar), 7.03 
(1H, t, J = 7.3 Hz, Ar), 4.44 (1H, d, J1,2 = 9.9 Hz, H-1), 3.93-3.85 (1H, m, H-6a), 3.77-3.65 
(2H, m, H-2 or H-3 or H-4, H-6b), 3.55-3.37 (3H, m, H-2 and/or H-3 and/or H-4, H-5). 
13
C 
NMR (MeOD, 360 MHz)  (ppm) 162.4, 159.2 (C-oxadiazole), 139.6, 130.2, 123.8, 118.8 
(Ar), 82.6, 79.1, 74.6, 73.2, 71.3 (C-1–C-5), 62.8 (C-6). Anal. Calcd. for C14H17N3O6 
(323.30): C, 52.01, H, 5.30; N, 13.00. Found: C, 52.11; H, 5.39; N, 13.11. 
 
4.9.8. 2-Acetamido-5-(-D-glucopyranosyl)-1,3,4-oxadiazole (28) 
From 20 (0.18 g, 0.62 mmol) according to General procedure IV (Section 4.9.1.). Purified by 
column chromatography (5:1 CHCl3–methanol) to yield 30 mg (41%) of 28 as a white 
amorphous product. [α]D = +38 (c 0.15, H2O); Rf : 0.28 (3:1 CHCl3–methanol); 
1
H NMR 
(D2O+MeOD, 360 MHz)  (ppm) 4.69 (1H, d, J1,2 = 9.9 Hz, H-1), 3.91 (1H, dd, J5,6a = 1.4 
Hz, J6a,6b  = 12.1 Hz, H-6a), 3.82-3.70 (2H, m, H-2 or H-3 or H-4, H-6b), 3.66-3.57 (2H, m, 
H-2 or H-3 or H-4, H-5), 3.52 (1H, pt, J = 9.2 Hz, H-2 or H-3 or H-4), 2.57 (3H, s, CH3). 
13
C 
NMR (D2O+MeOD, 360 MHz)  (ppm) 166.6 (NHCO, C-oxadiazole), 163.8 (C-oxadiazole), 
80.4, 76.6, 72.3, 71.5, 69.2 (C-1–C-5), 62.7 (C-6), 10.0 (CH3). Anal. Calcd. for C10H15N3O7 
(289.24): C, 41.52, H, 5.23; N, 14.53. Found: C, 41.59; H, 5.29; N, 14.62. 
 
4.9.9. 2-Benzamido-5-(-D-glucopyranosyl)-1,3,4-oxadiazole (30) 
From 21 (0.15 g, 0.43 mmol) according to General procedure IV (Section 4.9.1.). Purified by 





































































amorphous product. [α]D = +11 (c 0.13, DMSO); Rf : 0.26 (3:1 CHCl3–methanol); 
1
H NMR 
(MeOD, 360 MHz)  (ppm) 8.07 (2H, d, J = 7.2 Hz, Ar), 7.65-7.50 (3H, m, Ar), 4.66 (1H d, 
J1,2 = 9.8 Hz, H-1), 3.93 (1H, dd, J5,6a = 1.4 Hz, J6a,6b = 12.1 Hz, H-6a), 3.85 (1H, pt, J = 9.0 
Hz, H-2 or H-3 or H-4), 3.74 (1H, dd, J5,6b = 5.2 Hz, H-6b) 3.60-3.43 (3H, m, H-2 and/or H-3 
and/or H-4, H-5,). 
13
C NMR (MeOD, 360 MHz)  (ppm) 166.8 (NHCO, C-oxadiazole), 165.6 
(C-oxadiazole), 133.4, 130.4, 128.0, 124.6 (Ar), 82.8, 79.0, 74.6, 73.4, 71.2 (C-1–C-5), 62.7 
(C-6). Anal. Calcd. for C15H17N3O7 (351.31): C, 51.28, H, 4.88; N, 11.96. Found: C, 51.20; H, 
4.93; N, 12.06. 
 
4.9.10. 2-(2-Naphthamido)-5-(-D-glucopyranosyl)-1,3,4-oxadiazole (30) 
From 22 (0.16 g, 0.40 mmol) according to General procedure IV (Section 4.9.1.). Purified by 
column chromatography (8:1 CHCl3–methanol) to yield 73 mg (93%) of 30 as a white 
amorphous product. [α]D = +13 (c 0.10, DMSO); Rf : 0.13 (8:1 CHCl3–methanol); 
1
H NMR 
(DMSO-d6, 360 MHz)  (ppm) 7.81 (1H, bs, Ar), 7.35-7.10 (4H, m, Ar), 6.82 (2H, bs, Ar), 
3.87 (1H, d, J1,2 = 9.6 Hz, H-1), 3.15-3.02 (2H, m, H-2 or H-3 or H-4, H-6a,), 2.97-2.87 (1H, 
m, H-6b), 2.80-2.64 (3H, m, H-2 and/or H-3 and/or H-4, H-5,). 
13
C NMR (DMSO-d6, 360 
MHz)  (ppm) 164.8 (NHCO, C-oxadiazole), 164.2 (C-oxadiazole), 134.4-120.5 (Ar), 81.9, 
77.3, 72.9, 71.8, 69.9 (C-1–C-5), 61.0 (C-6). Anal. Calcd. for C19H19N3O7 (401.37): C, 56.86, 
H, 4.77; N, 10.47. Found: C, 56.79; H, 4.88; N, 10.38. 
 
4.9.11. 2-(4-tert-Butylbenzamido)-5-(-D-glucopyranosyl)-1,3,4- oxadiazole (31) 
From 23 (0.15 g, 0.37 mmol) according to General procedure IV (Section 4.9.1.). Purified by 
column chromatography (7:1 CHCl3–methanol) to yield 56 mg (76%) of 31 as a white 
amorphous product. [α]D = +13 (c 0.29, DMSO); Rf : 0.30 (7:1 CHCl3–methanol); 
1
H NMR 





































































(1H, d, J1,2 = 9.8 Hz, H-1), 3.92 (1H, m, H-6a), 3.84 (1H, pt, J = 9.1 Hz, H-2 or H-3 or H-4), 
3.72 (1H, dd, J5,6b = 4.6 Hz, J6a,6b = 12.0 Hz, H-6b), 3.62-3.42 (3H, m, H-2 and/or H-3 and/or 
H-4, H-5), 1.37 (9H, s, CH3). 
13
C NMR (MeOD, 360 MHz)  (ppm) 167.0 (NHCO, C-
oxadiazole), 165.4 (C-oxadiazole), 157.3, 127.9, 127.4, 121.8 (Ar), 82.9, 79.1, 74.6, 73.4, 
71.3 (C-1–C-5), 62.8 (C-6), 36.0 (Cq-tBu), 31.5 (CH3). Anal. Calcd. for C19H25N3O7 
(407.42): C, 56.01, H, 6.18; N, 10.31. Found: C, 56.12; H, 6.27; N, 10.21. 
 
4.9.12. 2-Acetamido-5-(-D-glucopyranosyl)-1,3,4-thiadiazole (32) 
From 24 (0.18 g, 0.59 mmol) according to General procedure IV (Section 4.9.1.). Purified by 
column chromatography (8:1 CHCl3–methanol) to yield 70 mg (92%) of 32 as a white 
amorphous product. [α]D = +25 (c 0.27, DMSO); Rf : 0.12 (8:1 CHCl3–methanol); 
1
H NMR 
(DMSO-d6, 360 MHz)  (ppm) 4.48 (1H, d, J1,2 = 9.0 Hz, H-1), 3.69 (1H, dd, J5,6a = 4.8 Hz, 
J6a,6b = 11.6 Hz, H-6a), 3.47-3.27 (4H, m, H-2, H-3, H-4, H-6b), 3.22-3.18 (1H, m, H-5), 2.19 
(3H, s, CH3). 
13
C NMR (DMSO-d6, 360 MHz)  (ppm) 168.5 (NHCO), 162.8, 158.9 (C-
thiadiazole), 81.5, 77.6, 76.7, 74.5, 69.9 (C-1–C-5), 61.1 (C-6), 22.3 (CH3). Anal. Calcd. for 
C10H15N3O6S (305.31): C, 39.34, H, 4.95; N, 13.76; S, 10.50. Found: C, 39.25; H, 4.86; N, 
13.65; S, 10.59. 
 
4.9.13. 2-Benzamido-5-(-D-glucopyranosyl)-1,3,4-thiadiazole (33) 
From 25 (0.11 g, 0.30 mmol) according to General procedure IV (Section 4.9.1.). Purified by 
column chromatography (8:1 CHCl3–methanol) to yield 35 mg (68%) of 33 as a white 
amorphous product. [α]D = +9 (c 0.20, DMSO); Rf : 0.13 (8:1 CHCl3–methanol); 
1
H NMR 
(DMSO-d6, 360 MHz)  (ppm) 8.09 (2H, d, J = 7.5 Hz, Ar), 7.66 (1H, pt, J = 7.2 Hz, Ar), 
7.56 (2H, pt, J = 7.5 Hz, Ar), 4.54 (1H, d, J1,2 = 8.7 Hz, H-1), 3.76-3.66 (1H, m, H-6a), 3.45 





































































H-5), 3.20 (1H, t, J = 8.7 Hz, H-2 or H-3 or H-4). 
13
C NMR (DMSO-d6, 360 MHz)  (ppm) 
165.5 (NHCO), 163.4, 160.2 (C thiadiazole), 133.2, 131.6, 128.9, 128.5 (Ar), 81.7, 77.6, 76.9, 
74.6, 70.0 (C-1–C-5), 61.2 (C-6). ESI-MS (positive mode) m/z: 368.08 [M+H]+. Anal. Calcd. 
for C15H17N3O6S (367.38): C, 49.04, H, 4.66; N, 11.44; S, 8.73. Found: C, 49.13; H, 4.75; N, 
11.53; S, 8.62. 
 
4.9.14. 2-(2-Naphthamido)-5-(-D-glucopyranosyl)-1,3,4-thiadiazole (34) 
From 26 (0.14 g, 0.34 mmol) according to General procedure IV (Section 4.9.1.). Purified by 
column chromatography (7:1 CHCl3–methanol) to yield 40 mg (57%) of 34 as a white 
amorphous product. [α]D = +10 (c 1.10, DMSO); Rf : 0.32 (7:1 CHCl3–methanol); 
1
H NMR 
(DMSO-d6, 360 MHz)  (ppm) 8.81 (1H, bs, Ar), 8.15-8.00 (4H, m, Ar), 7.72-7.60 (2H, m, 
Ar), 4.55 (1H, d, J1,2 = 8.9 Hz, H-1), 3.76-3.68 (1H, m, H-6a), 3.40-3.30 (4H, m, H-2 and/or 
H-3 and/or H-4, H-5, H-6b), 3.21 (1H, pt, J = 8.9 Hz, H-2 or H-3 or H-4). 
13
C NMR (DMSO-
d6, 360 MHz)  (ppm) 165.5 (NHCO), 163.2, 160.0 (C-thiadiazole), 134.9-122.8 (Ar), 81.6, 
77.6, 76.8, 74.5, 69.9 (C-1–C-5), 61.1 (C-6). Anal. Calcd. for C19H19N3O6S (417.44): C, 
54.67, H, 4.59; N, 10.07; S,7.68. Found: C, 54.56; H, 4.68; N, 10.01; S, 7.78. 
 
4.9.15. 2-(4-tert-Butylbenzamido)-5-(-D-glucopyranosyl)-1,3,4-thiadiazole (35) 
From 27 (0.18 g, 0.43 mmol) according to General procedure IV (Section 4.9.1.). Purified by 
column chromatography (7:1 CHCl3–methanol) to yield 60 mg (66%) of 35 as a white 
amorphous product. [α]D = +9 (c 1.00, DMSO); Rf : 0.36 (7:1 CHCl3–methanol); 
1
H NMR 
(DMSO-d6, 360 MHz)  (ppm) 8.07 (2H, d, J = 8.2 Hz, Ar), 7.59 (2H, d, J = 8.2 Hz, Ar), 4.55 
(1H, d, J1,2 = 8.6 Hz, H-1), 3.78-3.70 (1H, m, H-6a), 3.48 (1H, dd, J5,6b = 5.9 Hz, J6a,6b = 11.8 
Hz, H-6b), 3.41-3.30 (3H, m, H-2 and/or H-3 and/or H-4, H-5), 3.22 (1H, pt, J = 8.7 Hz, H-2 
or H-3 or H-4), 1.33 (9H, s, CH3). 
13





































































163.3, 160.0 (C-thiadiazole), 156.3, 128.7, 128.4, 125.7 (Ar), 81.7, 77.6, 76.9, 74.5, 70.0 (C-
1–C-5), 61.2 (C-6), 35.0 (Cq-tBu), 31.0 (CH3). Anal. Calcd. for C19H25N3O6S (423.48): C, 
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Synthesis of 2-(β-D-glucopyranosyl)-5-(substituted-amino)-1,3,4-oxa- and -thiadiazoles 
for inhibition of glycogen phosphorylase 











































X = O, S; R' = CH3, Ph, 2-Naphthyl, 4-tBu-C6H4
X = O, S; R = H, Ph, R'CO
X = O, S; R = H, Ph




















 Preparation of new anhydro-aldose semicarbazones and thiosemicarbazones. 
 Synthesis of 2-acylamino- or 2-arylamino-5-(β-D-glucopyranosyl)-1,3,4-oxa- and -
thiadiazoles. 
 Low micromolar inhibitor of glycogen phosphorylase. 
